Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15371MR)

This product GTTS-WQ15371MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15371MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7210MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ12620MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ3523MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ15704MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ12103MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ5423MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ480MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ3361MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW